#MSBlog: Alemtuzumab increases your chances of sustained or confirmed disability improvement compared to interferon-beta.
"Apologies for putting this poster up so late; it is from the Neuroimmunology Meeting in Porto a few weeks ago. I simply forgot. Its subject matter is self-explanatory!"
Labels: Alemtuzumab, disability, Porto